Related Experiment Video
Updated: Oct 5, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis
Lijuan Zhang1,2, Yun Huang2, Yun Lin2
1The School of Clinical Medicine, Fujian Medical University, Fuzhou, People's Republic of China.
Objectives:
Several studies have demonstrated the expression status of CD56 was associated with prognosis in multiple myeloma (MM) patients, the prognostic significance remains controversial. Here, the prognostic value of CD56 is further investigated in MM patients.
Methods:
We systematically searched the databases including PubMed, EMBASE, Web of Science and the Cochrane Library. The hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to evaluate the relationship between CD56 and overall survival (OS) and progress-free survival (PFS).
Results:
A total of 14 studies covering 1365 patients were included in this meta-analysis. The results revealed that CD56 negativity in MM was associated with poorer OS (HR = 1.83, 95% CI = 1.29-2.60, P = 0.001) and PFS (HR = 1.57, 95% CI = 1.27-1.95, P = 0.000). Subgroup analysis further demonstrated that there was an effect of treatment regimen, detection method, survival analysis, study region and the cut-off value of CD56 on CD56 expression.
Discussion And Conclusion:
The meta-analysis suggested that CD56 negative patients had a poor prognosis for OS in Asian patients and for PFS in non-Asian patients. Novel drugs didn't show a significant improvement or overcome on the adverse prognosis brought by CD56 negativity. For patients undergone autologous stem-cell transplantation (ASCT), the poor prognosis was overcome by the treatment, which shed a light on the prognostic judgment and individualized treatment.
Insights
CD56 negativity in multiple myeloma (MM) indicates a poorer prognosis for overall survival (OS) and progression-free survival (PFS). However, autologous stem-cell transplantation (ASCT) can overcome this adverse outcome, guiding individualized treatment strategies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- CD56 expression is a known prognostic factor in multiple myeloma (MM), but its significance remains debated.
- Previous studies indicate a correlation between CD56 status and patient outcomes, necessitating further investigation.
Purpose of the Study:
- To systematically evaluate the prognostic value of CD56 expression in patients with multiple myeloma (MM).
- To clarify the association between CD56 negativity and overall survival (OS) and progression-free survival (PFS) in MM.
Main Methods:
- A comprehensive meta-analysis was conducted, searching major databases (PubMed, EMBASE, Web of Science, Cochrane Library).
- Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to assess the relationship between CD56 status and survival outcomes.
Main Results:
- The meta-analysis included 14 studies with 1365 MM patients.
- CD56 negativity was significantly associated with poorer OS (HR=1.83) and PFS (HR=1.57).
- Subgroup analyses revealed that treatment regimen, detection method, study region, and CD56 cut-off values influenced the results.
Conclusions:
- CD56-negative MM patients face a poorer prognosis, particularly Asian patients for OS and non-Asian patients for PFS.
- Novel drugs did not significantly improve outcomes for CD56-negative patients.
- Autologous stem-cell transplantation (ASCT) can overcome the adverse prognosis associated with CD56 negativity, informing personalized treatment approaches.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015